# Signals Article: Putative Target P15529 for Group A Streptococcus Vaccine
Background
Group A Streptococcus (GAS) is a significant human pathogen responsible for a wide range of diseases, from mild infections like pharyngitis to severe conditions such as rheumatic fever and necrotizing fasciitis. Developing a vaccine against GAS could drastically reduce the global burden of these infections and associated complications.
Data-mining rationale
In a recent reanalysis effort, UniProt entry P15529 was identified as a putative target for a GAS vaccine. This candidate emerged from cross-referencing UniProt's reviewed human entries with expression-profiling studies in the NCBI GEO database, specifically datasets GDS:200019491 and GDS:200002713. Although P15529 is present in these studies, it has not been associated with any registered Phase 1 or higher clinical programs, suggesting its potential as an unexplored target.
Why prior analyses may have missed this
Many of the GEO datasets containing P15529 predate modern empirical-Bayes statistical methods, such as limma, which are crucial for accurate differential expression analysis. The absence of proper multiple-testing correction in earlier analyses may have led to the underestimation of P15529's potential as a vaccine target. Additionally, the lack of integration with pathway and tissue-specific databases may have obscured its relevance.
Reasoning for further validation
To fully assess the potential of P15529 as a vaccine target, several steps are recommended. Re-analyzing the matched GEO datasets using limma with Benjamini-Hochberg FDR correction will provide a more accurate picture of differential expression. Validation of top differentially-expressed genes by qPCR in an independent cohort is essential to confirm findings. Checking tissue specificity in GTEx and the Human Protein Atlas will help determine the target's relevance in the context of GAS infection. Running pathway analyses using STRING or OmniPath will provide insights into the biological context of P15529. If validated, assessing the druggability of P15529 via DGIdb and ChEMBL will be crucial for potential therapeutic development.